Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

California Senate weighs Rx PSE

This article was originally published in The Tan Sheet

Executive Summary

The California Senate's Appropriations Committee May 28 approves a bill making it illegal in the state to buy ephedrine- or pseudophedrine-containing products without a prescription. The Consumer Healthcare Products Association initiated an Internet campaign against the bill's passage, warning California consumers they could lose OTC access to antihistamine and decongestant products such as Zyrtec-D, Sudafed and Claritin-D. The trade group notes the state would incur costs from increased health insurance premiums for state employees and could lose $4.5 million in sales tax revenue if ephedrine and PSE products become Rx-only. CHPA argues that existing federal law and electronic logbooks to monitor purchases of methamphetamine precursors have helped decrease the number of illicit meth labs. Oregon so far is the only state to enact a prescription-only law for all PSE drugs (1"The Tan Sheet" Feb. 23, 2009, p. 3)

You may also be interested in...



Pharmacist-only PSE sales in Louisiana

A law requiring sales of OTC drugs containing ephedrine, pseudoephedrine and phenylpropanolamine to be done by licensed pharmacists takes effect Aug. 15. Louisiana lawmakers this year enacted the law, which requires retailers to conduct electronic logging of transactions, to curb illicit methamphetamine production by controlling access to precursors. Oregon already has moved PSE- and ephedrine-containing products to Rx-status and legislation is pending in California to make the products prescription only (1"The Tan Sheet" June 8, 2009, In Brief)

Wyden To Propose Prescription-Only Status For Pseudoephedrine

Legislation drafted by Sen. Ron Wyden would require prescriptions for all products containing the methamphetamine precursor pseudoephedrine

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel